Product information and disease description Product description Product information

Co-prescribed/Concomitant therapies

6 evidence topics · 5 sources

Postoperative regimen: first-in-human study

“The postoperative regimen included a weekly taper of topical steroid/antibiotic combination from Q4H to Q6H to Q8H over a 3-week period. IOP-lowering drops were not reintroduced unless clinically necessary.” (opens the source at this quote in a new tab)

Masking drops: phase 1/2 trial

“A total of 104 patients were randomized 2:1:1 to receive the 78 mcg BIM-IOL System (N=51) and 39 mcg BIM-IOL System (N=23) with daily administration of artificial tear drops, or a commercially available monofocal IOL from Alcon, Bausch + Lomb or Johnson & Johnson with twice-daily administration of timolol eye drops as the control group (N=30).” (opens the source at this quote in a new tab)

Preoperative washout of IOP-lowering medications

“Informed by our Phase 1/2 data, we have implemented minor protocol modifications to the inclusion and exclusion criteria. Key changes include tightening the baseline IOP range, enrolling patients on up to two IOP-lowering medications, tailoring washout periods based on drug class pharmacokinetics, and standardizing IOP measurement timing.” (opens the source at this quote in a new tab)

Adjunctive topical IOP-lowering medication after implantation

“98% of evaluable patients (48 of 49) in the 78-mcg dose group and 96% of evaluable patients (22 of 23) in the 39-mcg dose group were free from all topical IOP-lowering medications.” (opens the source at this quote in a new tab)

“All 16 subjects in the 75 μg and 150 μg cohorts remained off glaucoma drops through month 36. A single subject in the 300 μg arm required reintroduction of a topical IOP-lowering medication at month 30.” (opens the source at this quote in a new tab)

Concomitant topical ocular therapy: Lumigan labeling

“LUMIGAN® 0.01% may be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.” (opens the source at this quote in a new tab)

Combination with MIGS, SLT, or later angle procedures

“The system can be used during routine cataract surgery, either with MIGS or as a standalone procedure, in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).” (opens the source at this quote in a new tab)

“Second, it leaves the angle untouched, allowing for concurrent or subsequent gonioscopic intervention, or subsequent selective laser trabeculoplasty.” (opens the source at this quote in a new tab)

Clinical data on use combined with MIGS or SLT

No evidence found.